Total
0
Shares
Proteomics receives CE Mark for kidney disease test
  • Proteomics has secured CE Mark registration for its kidney disease test, PromarkerD
  • Promarker D is a simple blood test that uses a uniques protein 'fingerprint' to detect the disease up to four years before clinical symptoms appear
  • This announcement follows the launch of PromarkerD in Spain, where diabetes affects 10 per cent of the adult population
  • Proteomics is up 1.49 per cent on the ASX and is selling shares for 34 cents apiece

Proteomics International Laboratories has secured CE Mark registration for its PromarkerD as a diagnostic medical device.

PromarkerD is a world-first test for predicting the beginning of diabetic kidney disease.

CE marking is a certification mark that indicates a fitting in with health, safety and environmental protection standards for products sold within the European Economic Area.

The test assesses the risk of diabetic kidney disease in patients with type 2 diabetes. Chronic kidney disease is one of the major complications that can come from diabetes and if unchecked can lead to dialysis or a kidney transplant.

Promarker D is a simple blood test that uses a unique protein 'fingerprint' to detect the disease up to four years before clinical symptoms appear.

"The CE Mark is another important milestone for PromarkerD as we move forward with new deals in the region," Managing Director Richard Lipscombe said.

"CE Mark registration reflects the strength of the clinical and technical data that we have collected in developing our ground-breaking test that could help save healthcare systems billions of dollars," he added.

This announcement follows the launch of PromarkerD in Spain, where diabetes affects 10 per cent of the adult population (3.6 million people).

The World Health Organisation believes that the European Region is home to 60 million adults with diabetes and currently 1 in 3 have chronic kidney disease.

"PromarkerD could aid clinical decision-making by identifying at-risk individuals for earlier therapeutic intervention and help to minimise the effect of the disease," the company stated.

Proteomics is up 1.49 per cent on the Australian Securities Exchange and is selling shares for 34 cents apiece at 12:55 pm AEDT.


Subscribe


PIQ by the numbers
More From The Market Herald
Mach7 Technologies (ASX:M7T) delivers positive EBITDA and NPAT growth

" Mach7 Technologies (ASX:M7T) delivers positive EBITDA and NPAT growth

Mach7 Technologies (M7T) has seen a rise in its share price today after releasing its half-year results for the period ended December 31,
Noxopharm (ASX:NOX) receives approval from U.S. FDA for Veyonda

" Noxopharm (ASX:NOX) receives approval from U.S. FDA for Veyonda

Noxopharm (NOX) has received approval from the U.S. FDA for the Investigational New Drug Application (IND) for Veyonda.
MGC Pharma (ASX:MXC) - Co Founder and Managing Director, Roby Zomer - The Market Herald

" MGC Pharmaceuticals (ASX:MXC) sees 85pc increase in Mercury Pharma orders

MGC Pharmaceuticals (MXC) has received an 85 per cent increase to its January purchase order volume over the past week.
ResApp Health (ASX:RAP) - Managing Director & CEO, Tony Keating - The Market Herald

" ResApp Health (ASX:RAP) to raise $5M for European commercialisation

ResApp Health (RAP) will raise $5 million to accelerate its European commercialisation and generate working capital.